Tonix announces FDA approval of Tonmya for treatment of fibromyalgia
FDA Approval: Tonix Pharmaceuticals announced that the FDA has approved Tonmya, a new treatment for fibromyalgia in adults, marking the first new therapy for this condition in over 15 years.
Unique Formulation: Tonmya is a non-opioid, once-daily bedtime analgesic with a sublingual formulation designed for rapid absorption into the bloodstream.
Clinical Trials: The approval was based on two Phase 3 clinical trials involving nearly 1,000 patients, which demonstrated significant pain reduction compared to placebo after 14 weeks.
Availability: Tonmya is expected to be available for adult patients with fibromyalgia in the U.S. starting in the fourth quarter of this year.
Trade with 70% Backtested Accuracy
Analyst Views on TNXP
About TNXP
About the author
TNXP Shares Plummet for Four Consecutive Days as Investors Anticipate Drug Pipeline Returns
Tonix Pharmaceuticals Updates: Tonix is evaluating its Tonmya drug for treating major depressive disorder and acute stress disorder, with plans to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 aimed at seasonal prevention of Lyme disease.
Stock Performance: Shares of Tonix Pharmaceuticals (TNXP) have fallen for four consecutive days, although retail sentiment around the stock has increased by 92% in the past 24 hours, with analysts rating it a 'Buy'.
Drug Approvals and Usage: The U.S. FDA approved Tonix's Tonmya for managing fibromyalgia in adults, and over 2,500 patients have started treatment with it since its launch in November.
Future Pipeline Candidates: Tonix's pipeline includes TNX-2900 for treating Prader-Willi syndrome, TNX-1500 for preventing kidney transplant rejection, and TNX-1900 for treating migraines, with analysts suggesting a potential upside for the stock.
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
Tonix Pharmaceuticals Reports Strong Q4 Results with Nearly Doubling Sales
- Strong Sales Performance: Tonix Pharmaceuticals reported fourth-quarter sales of $5.39 million, exceeding market expectations of $2.88 million, although the company posted a loss of $3.98 per share, missing the anticipated loss of $3.16, indicating robust product demand.
- Pipeline Progress: Since its launch in November 2025, over 1,500 healthcare providers have prescribed Tonmya, with approximately 2,500 patients initiating treatment and cumulative prescriptions totaling around 4,200, reflecting increasing market acceptance.
- Robust Cash Position: As of December 31, 2025, Tonix Pharmaceuticals holds approximately $207.6 million in cash and cash equivalents, which is expected to support operations into the first quarter of 2027, enhancing financial stability.
- Market Performance Analysis: Despite a 1.12% increase in premarket trading to $13.56, Tonix's stock price remains below both the 20-day and 100-day simple moving averages, indicating a bearish trend in the short term, prompting investors to exercise caution.
Tonix Pharmaceuticals Reports Q4 Loss Amid Early Drug Adoption
- Early Drug Adoption: Following the commercial launch of Tonmya on November 17, 2025, over 1,500 healthcare providers have prescribed the drug, indicating favorable prescriber uptake that is expected to enhance the company's competitive position in the fibromyalgia treatment market.
- Financial Performance Analysis: Tonix reported approximately $534 million in revenue for Q4 2025, a significant increase from $2.6 million a year earlier, although the net loss of $46.9 million highlights the financial pressures faced while expanding market presence.
- Future Development Plans: The company plans to meet with the FDA in 2027 to discuss Phase 2/3 development options for TNX-4800, with a field study expected to begin in 2027, further expanding its market potential in Lyme disease prevention.
- Positive Investor Sentiment: Despite a 14% decline in TNXP stock this year, investor reactions on Stocktwits have been “extremely bullish” regarding Tonix's latest earnings report, reflecting confidence in the company's future growth prospects.
Tonix Pharmaceuticals Q4 Earnings Beat Expectations with Revenue Surge
- Earnings Performance: Tonix Pharmaceuticals reported a Q4 GAAP EPS of -$3.98, missing expectations by $0.82, indicating ongoing challenges in achieving profitability.
- Revenue Surge: The company achieved revenue of $5.39 million in Q4, representing a 108.9% year-over-year increase, exceeding market expectations by $2.42 million, which suggests a significant rise in product demand that could lay the groundwork for future growth.
- Cash Position: As of December 31, 2025, Tonix had approximately $207.6 million in cash and cash equivalents, a substantial increase from $98.8 million as of December 31, 2024, enhancing its operational flexibility and capacity for future investments.
- Financing Initiative: Tonix announced a $20 million registered direct offering aimed at funding its product expansion and R&D efforts, reflecting the company's confidence in its growth prospects.
Tonix Pharmaceuticals Reports Q4 Net Loss of $46.91 Million
Company Overview: Tonix Pharmaceuticals is a biopharmaceutical company focused on developing therapies for various medical conditions.
Financial Performance: The company reported a net income of USD 46.91 million for the fourth quarter.
Market Position: Tonix Pharmaceuticals is actively working on expanding its product pipeline and enhancing its market presence.
Future Outlook: The company aims to leverage its recent financial performance to support ongoing research and development initiatives.
TNXP Shares Plummet for Four Consecutive Days as Investors Anticipate Drug Pipeline Returns
Tonix Pharmaceuticals Updates: Tonix is evaluating its Tonmya drug for treating major depressive disorder and acute stress disorder, with plans to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 aimed at seasonal prevention of Lyme disease.
Stock Performance: Shares of Tonix Pharmaceuticals (TNXP) have fallen for four consecutive days, although retail sentiment around the stock has increased by 92% in the past 24 hours, with analysts rating it a 'Buy'.
Drug Approvals and Usage: The U.S. FDA approved Tonix's Tonmya for managing fibromyalgia in adults, and over 2,500 patients have started treatment with it since its launch in November.
Future Pipeline Candidates: Tonix's pipeline includes TNX-2900 for treating Prader-Willi syndrome, TNX-1500 for preventing kidney transplant rejection, and TNX-1900 for treating migraines, with analysts suggesting a potential upside for the stock.
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
Tonix Pharmaceuticals Reports Strong Q4 Results with Nearly Doubling Sales
- Strong Sales Performance: Tonix Pharmaceuticals reported fourth-quarter sales of $5.39 million, exceeding market expectations of $2.88 million, although the company posted a loss of $3.98 per share, missing the anticipated loss of $3.16, indicating robust product demand.
- Pipeline Progress: Since its launch in November 2025, over 1,500 healthcare providers have prescribed Tonmya, with approximately 2,500 patients initiating treatment and cumulative prescriptions totaling around 4,200, reflecting increasing market acceptance.
- Robust Cash Position: As of December 31, 2025, Tonix Pharmaceuticals holds approximately $207.6 million in cash and cash equivalents, which is expected to support operations into the first quarter of 2027, enhancing financial stability.
- Market Performance Analysis: Despite a 1.12% increase in premarket trading to $13.56, Tonix's stock price remains below both the 20-day and 100-day simple moving averages, indicating a bearish trend in the short term, prompting investors to exercise caution.
Tonix Pharmaceuticals Reports Q4 Loss Amid Early Drug Adoption
- Early Drug Adoption: Following the commercial launch of Tonmya on November 17, 2025, over 1,500 healthcare providers have prescribed the drug, indicating favorable prescriber uptake that is expected to enhance the company's competitive position in the fibromyalgia treatment market.
- Financial Performance Analysis: Tonix reported approximately $534 million in revenue for Q4 2025, a significant increase from $2.6 million a year earlier, although the net loss of $46.9 million highlights the financial pressures faced while expanding market presence.
- Future Development Plans: The company plans to meet with the FDA in 2027 to discuss Phase 2/3 development options for TNX-4800, with a field study expected to begin in 2027, further expanding its market potential in Lyme disease prevention.
- Positive Investor Sentiment: Despite a 14% decline in TNXP stock this year, investor reactions on Stocktwits have been “extremely bullish” regarding Tonix's latest earnings report, reflecting confidence in the company's future growth prospects.
Tonix Pharmaceuticals Q4 Earnings Beat Expectations with Revenue Surge
- Earnings Performance: Tonix Pharmaceuticals reported a Q4 GAAP EPS of -$3.98, missing expectations by $0.82, indicating ongoing challenges in achieving profitability.
- Revenue Surge: The company achieved revenue of $5.39 million in Q4, representing a 108.9% year-over-year increase, exceeding market expectations by $2.42 million, which suggests a significant rise in product demand that could lay the groundwork for future growth.
- Cash Position: As of December 31, 2025, Tonix had approximately $207.6 million in cash and cash equivalents, a substantial increase from $98.8 million as of December 31, 2024, enhancing its operational flexibility and capacity for future investments.
- Financing Initiative: Tonix announced a $20 million registered direct offering aimed at funding its product expansion and R&D efforts, reflecting the company's confidence in its growth prospects.
Tonix Pharmaceuticals Reports Q4 Net Loss of $46.91 Million
Company Overview: Tonix Pharmaceuticals is a biopharmaceutical company focused on developing therapies for various medical conditions.
Financial Performance: The company reported a net income of USD 46.91 million for the fourth quarter.
Market Position: Tonix Pharmaceuticals is actively working on expanding its product pipeline and enhancing its market presence.
Future Outlook: The company aims to leverage its recent financial performance to support ongoing research and development initiatives.
